Clinical Trials
Low Rates of Stroke and Major Bleeding with Rivaroxaban Confirmed by Global Study
XANTUS pooled results study
Results of the pooled analysis of the global XANTUS realworld study programme were announced recently at the European Society of Cardiology ESC Congress in Barcelona Spain The study investigated the use of the nonvitamin K antagonist oral anticoagulant NOAC rivaroxaban for stroke prevention in patients with nonvalvular Atrial Fibrillation AF irregu...
THE AGGREGATE SAFETY ASSESSMENT PLAN
A valuable tool for clinical trial safety planning
Recently a Drug Information Association American Statistical Associationsponsored Interdisciplinary Safety Evaluation working group published a recommended approach to the aggregate assessment of clinical trial safety data
